Targeted therapy in the treatment of malignant gliomas

OncoTargets and Therapy

Volumn 2, Issue , 2009, Pages 115-133

  Lukas, Rimas V ^a   Boire, Adrienne ^a   Nicholas, M Kelly ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Angiogenesis; EGFR; Glioma; HDAC; mTOR; Ras

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFLIBERCEPT; ATRASENTAN; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CEDIRANIB; CELECOXIB; CETUXIMAB; CILENGITIDE; DEFOROLIMUS; EMD 55900; ENZASTAURIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; IMATINIB; IRINOTECAN; ISOTRETINOIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEVINOLIN; NIMOTUZUMAB; OSAG 101; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAPAMYCIN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE SEMISODIUM; VORINOSTAT;

ANGIOGENESIS; ASTROCYTOMA; BRAIN TUMOR; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER IMMUNIZATION; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DELIVERY SYSTEM; DRUG TARGETING; EXTRACELLULAR MATRIX; GENE THERAPY; GLIOBLASTOMA; HUMAN; METASTASIS; NEURAL STEM CELL; NONHUMAN; OLIGODENDROGLIOMA; REVIEW; T CELL LYMPHOMA;

EID: 77953421100     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumors of the Central Nervous System (4th edition). Lyon, France: International Agency For Research on Cancer; 2007.
2. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A. 1987;84(19):6899-6903.
3. Wickstrand CJ, McClendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res. 1997;57(18):4130-4140. (Pubitemid 27427708)
4. Biernat W, Huang H, Yokoo H, Kleihues P, Ohgaki H. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol. 2004;14(2):131-136. (Pubitemid 38656384)
5. Pelloski CE, Ballman KV, Furth AF, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol. 2007;25(16):2288-2294.
6. Shinojima N, Tada K, Siraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003;63(20):6962-6970. (Pubitemid 37322983)
7. Reifenberger J, Reifenberger G, Ichimura K, Schmidt EE, Wechler W, Collins VP. Epidermal growth factor expression in oligodendroglial tumors. Am J Pathol. 1996;149(1):29-35. (Pubitemid 26230975)
8. Chakravarti A, Seiferheld W, Tu X, et al. Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2005;62(2):318-327. (Pubitemid 40704445)
9. Yarden Y, Shiloh BZ. Snapshot: EGFR signaling pathway. Cell. 2007;131(5):1018.
10. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008;27(41):5497-5510.
11. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase Akt pathway in human cancer. Nat Rev Cancer. 2002;2(7):489-501. (Pubitemid 37328931)
12. Endersby R, Baker SJ. PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene. 2008;27:5416-5430.
13. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353(19):2012-2024. (Pubitemid 41609094)
14. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005;97(12):880-887. (Pubitemid 41417939)
15. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786-792. (Pubitemid 40271173)
16. Gallia GL, Rand V, Siu I-M, et al. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res. 2006;4(10):709-714. (Pubitemid 44683311)
17. Broderick DK, Di C, Parrett TJ, et al. Mutations of PI3KCA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res. 2004;64(15):5048-5050.
18. Liu R, Tian B, Gearing M, Hunter S, Ye K, Mao Z. Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion. Proc Natl Acad Sci U S A. 2008;105(21):7570-7575. (Pubitemid 351830059)
19. Schuller U, Ruiter M, Herms J, Kretzschmar HA, Grabson-Frodl E. Absence in the mutations to AKT1 oncogene in glioblastomas and medulloblastomas. Acta Neuropathol. 2008;115(3):367-368.
20. Faillot T, Magdelenat H, Mady E, et al. A phase one study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. Neurosurgery. 1996;39(3):478-483. (Pubitemid 26292020)
21. Stragliotto G, Vega F, Stasieski P, Gropp P, Poisson M, Delattre JY. Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. Eur J Cancer. 1996;32A(4):636-640. (Pubitemid 26156577)
22. Ramos TC, Figueredo J, Catala M, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther. 2006;5(4):375-379.
23. Wigoda Z, Kula D, Bierzynska-Macyszynz G, et al. Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors. Hybridoma (Larchmt). 2006;25(3):125-132. (Pubitemid 43967697)
24. Combs SE, Heeger S, Haselmann R, Edler L, Debus J, Schulz-Ertner D. treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) - phase I/II trial: study protocol. BMC Cancer. 2006;6:133. (Pubitemid 44150676)
25. Yang W, Wu G, Barth RF, et al. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin Cancer Res. 2008;14(3):883-891. (Pubitemid 351231173)
26. Casaco A, Lopez G, Garcia I, et al. Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma. Cancer Biol Ther. 2008;7(3):333-339. (Pubitemid 351847044)
27. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol. 2008;20(5):267-275.
28. Heimberger AB, Crotty LE, Archer GE, Hess KR, Wickstrand CJ, Friedman AH. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res. 2003;9(11):4247-4254.
29. Doherty L, Gigas DC, Kesari S, et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology. 2006;67(1):156-158. (Pubitemid 44305484)
30. Ermoian RP, Kaprealian T, Lamborn KR, et al. Signal transduction molecules in gliomas of all grades. J Neurooncol. 2009;91(1):19-26.
31. Parry L, Maynard JH, Patel A, et al. Molecular analysis of the TSC1 and TSC2 tumor suppressor genes in sporadic glial and glioneuronal tumors. Hum Genet. 2000;107(4):350-356. (Pubitemid 30827078)
32. Sorenson AG, Batchelor TT, Wen PY, Zhang WT, Jain RK. Response criteria for glioma. Nat Clin Pract Oncol. 2008;5(11):634-644.
33. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. J Clin Oncol. 2005;23(23):5294-5304. (Pubitemid 46206983)
34. Chang SM, Wen P, Cloughesy T, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005;23(4):357-361. (Pubitemid 40980358)
35. Shinohara ET, Cao C, Niermann K, et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene. 2005;24(35):5414-5422. (Pubitemid 43080085)
36. Goudar RK, Shi Q, Hjelmeland MD, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther. 2005;4(1):101-112. (Pubitemid 40268071)
37. Knobbe CB, Reifenberger J, Reifenberger G. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS, and BRAF in glioblastomas. Acta Neuropathol. 2004;108(6):467-470. (Pubitemid 39534587)
38. Sebti SM. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell. 2005;7(4):297-300.
39. Jeuken J, van den Broecke C, Gijsen S, Boots-Sprenger S, Wesseling P. Ras/Raf pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol. 2007;114(2):121-133.
40. Feldkamp MM, Lau N, Roncari L, Guha A. Isotype-specific Ras.GTPlevels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res. 2001;61(11):4425-4431. (Pubitemid 32685770)
41. Feldkamp MM, Lala P, Lau N, Roncari L, Guha A. Expression of activated epidermal growth factor receptors Ras-guanosine triphosphate and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery. 1999;45(6):1442-1453.
42. Chakravarti A, Chakladar A, Delaney MA, Latham DE, Loeffler LS. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a Ras-dependant manner. Cancer Res. 2002;62(15):4307-4315. (Pubitemid 34827287)
43. Haas-Kogan DA, Banerjee A, Kocak M, et al. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Neuro Oncol. 2008;10(3):341-347.
44. Moyal EC, Laprie A, Dellanes M, et al. Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2007;68(5):1396-1401. (Pubitemid 47176810)
45. Cloughesy TF, Kuhn J, Robbins HI, et al. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing anti-epileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2006;24(22):3651-3656. (Pubitemid 46630540)
46. Cloughesy TF, Wen PY, Robbins HI, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2006;24(22):3651-3656.
47. Fouladi M, Nicholson HS, Zhou T, et al. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study. Cancer. 2007;110(11):2535-2541. (Pubitemid 350174941)
48. Larner J, Jane J, Laws E, Packer R, Myers C, Shaffrey M. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol. 1998;21(6):579-583. (Pubitemid 28558348)
49. Lustig R, Mikkelson T, Lesser G, et al. Phase II pre-radiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. Neuro Oncol. 2008;10(6):1004-1009.
50. Kazantsev AG, Thompsen LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov. 2008;7(10):854-868.
51. da Fonesca CO, Linden R, Futuro D, Gattass CR, Quirico-Santos T. Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol. Arch Immunol Ther Exp. 2008;56(4):267-276.
52. Smith KT, Workman JL. Histone deacetylase inhibitors: anticancer compounds. Int J Biochem Cell Biol. 2008; doi:10.1016j. biocel.2008.09.008.
53. Sudakin V, Yen TJ. Targeting mitosis for anti-cancer therapy. Biodrugs. 2007;21(4):225-233.
54. Yin D, Ong GM, Hu J, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res. 2007;13(3):1045-1052. (Pubitemid 46340384)
55. Camphausen, K, Cerna D, Scott T, et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer. 2005;114(3):380-386. (Pubitemid 40279957)
56. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetlyase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001;276(39):36734-36741. (Pubitemid 37384288)
57. Appels NM, Beijnen JH, Schellens JH. Development of farnesyl transferase inhibitors: a review. Oncologist. 2005;10(8):565-578. (Pubitemid 41429120)
58. Zujewski J, Horak ID, Bol CJ, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 2000;18(4):927-941. (Pubitemid 30106625)
59. Jones HA, Hahn SM, Bernhard E, McKenna WG. Ras inhibitors and radiation therapy. Semin Radiat Oncol. 2001;11(4):328-337.
60. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-1186.
61. White CW, Sondheimer HM, Crouch EC, Wilson H, Fan LL. Treatment of pulmonary hemangiomatosis with recombinant interferon alpha-2a. N Engl J Med. 1989;320(18):1197-1200. (Pubitemid 19124302)
62. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000;60(5):1383-1387. (Pubitemid 30152011)
63. Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst. 1972;48(2):347-356.
64. Das S, Srikanth M, Kessler JA. Cancer stem cells and glioma. Nat Clin Pract Neurol. 2008;4(8):427-435.
65. Wakabayashi T, Kayama T, Nishikawa R, et al. A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study). Jpn J Clin Oncol. 2008;38(10):715-718.
66. Buckner JC, Schomberg PJ, McGinnis WL, et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer. 2001;92(2):420-433.
67. Dillman RO, Shea WM, Tai DF, et al. Interferon-alpha2a and 13-cis-retinois acid with radiation treatment for high grade glioma. Neuro Oncol. 2001;3(1):35-41.
68. Chang SM, Barker FG 2nd, Huhn SL, et al. High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma. J Neurooncol. 1998;37(2):169-176.
69. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91(9):4082-4085.
70. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173(3):699-703.
71. Chang SM, Lamborn KR, Malec M, et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2004;60(2):353-357. (Pubitemid 39233451)
72. Kesari S, Schiff D, Henson JW, et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol. 2008;10(3):300-308.
73. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res. 2006;12(17):5018-5022. (Pubitemid 44453326)
74. Shibuya M. Vascular endothelial growth factor-dependant and - independent regulation of angiogenesis. BMB Rep. 2008;41(4):278-286. (Pubitemid 351656921)
75. Kaur B, Tan C, Brat DJ, Post DE, Van Meir EG. Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol. 2004;70(2): 229-243. (Pubitemid 39545734)
76. Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25(30):4714-4721. (Pubitemid 350086472)
77. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4(4):314-322. (Pubitemid 38525287)
78. Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. 2005;69(1-2):56-63. (Pubitemid 40410468)
79. Fine HA, Kim L, Albert PS, et al. A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin Cancer Res. 2007;13(23):7101-7106. (Pubitemid 350276894)
80. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13(4):1253-1259. (Pubitemid 46424067)
81. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722-4729.
82. Cloughesy TF. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent treatment-refractory glioblastoma (GBM). ASCO Meeting Abstract. 2008. No. 2010b.
83. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety, and patterns of response and recurrence in patients with high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009;91(3):329-336.
84. Lai A, Filka E, McGibbon B, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys. 2008;71(5):1372-1380.
85. Sathornsumetee S, Cao Y, Marcello JE, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol. 2008;26(2):271-278.
86. Gomez-Manzano C, Holash J, Fueyo J, et al. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol. 2008;10(6):940-945.
87. Batchelor TT, Sorenson AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11(1):83-95. (Pubitemid 46075199)
88. Harland SP, Kuc RE, Pickard JD, Davenport AP. Characterization of endothelin receptors in human brain cortex, gliomas, and meningiomas. J Cardiovasc Phamacol. 1995;26(Suppl 3):S408-S411.
89. Spinella F, Rosano S, DiCastor V, et al. Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells. Cancer Res. 2007;67(4):1725-1734. (Pubitemid 46383399)
90. Phuphanich S, Carson KA, Grossman SA, et al. Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro Oncol. 2008;10(4):617-623.
91. Guzman M, Duarte MJ, Blazquez C, et al. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. (Pubitemid 44050919)
92. Reardon DA, Quinn JA, Vredenburgh J, et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer. 2005;103(2):329-338. (Pubitemid 40129293)
93. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis ad lymphangiogenesis. Nat Rev Cancer. 2008;8(8):604-617.
94. Nabors LB, Mikkelson T, Rosenfeld SS, et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol. 2007;25(13):1651-1657.
95. MacDonald TJ, Stewart CF, Kocak M, et al. Phase I clinical trial of celengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol. 2008;26(6):919-924.
96. Sanai N, Alvarez-Bullya A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med. 2005;353(8):811-822.
97. Sanai N, Tramontin AD, Quinones-Hinojosa A, et al. Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature. 2004;427(6976):740-744. (Pubitemid 38294593)
98. Eriksson P, Perfilieva E, Bjork-Erikkson T, et al. Neurogenesis in the adult human hippocampus. Nat Med. 1984(11):1313-1317.
99. Bao S, Wu Q, McClendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756-760. (Pubitemid 44949604)
100. Rich JN. Cancer stem cells in radiation resistance. Cancer Res. 2007;67(19):8980-8984. (Pubitemid 47535877)
101. Griffero F, Daga A, Marrubi D, et al. Different response of human glioma tumor-initiating cells to EGFR kinase inhibitors. J Biol Chem. 2009;284(11):7138-7148.
102. Eyler CE, Foo WC, LaFiura KM, McLendon RE, Hjelmeland AB, Rich JN. Brain cancer stem cells display sensitivity to Akt inhibition. Stem Cells. 2008;26(12):3027-13026
103. Bao S, Wu Q, Li Z, et al. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 2008;68(15):6043-6048.
104. Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A. 2000;97(23):12846-12851. (Pubitemid 30840504)
105. Aboody KS, Najbauer J, Danks MK. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther. 2008;15(10):739-752. (Pubitemid 351627357)
106. Zhao D, Najbauer J, Garcia E, et al. Neural cell tropism to glioma: critical role of tumor hypoxia. Mol Cancer Res. 2008;6(12):1819-1829.
107. Tyler MA, Ulasov IV, Sonabend AM, et al. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther. 2009;16(2):262-278.
108. Sonabend AM, Ulasov IV, Tyler MA, Rivera AA, Mathis JM, Lesniak MS. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells. 2008;26(3):831-841.
109. Dent P, Yacoub A, Park M, et al. Searching for a cure: gene therapy for glioblastoma. Gene Ther. 2008;7(9):1335-1340.
110. Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol. 2003;21(13):2508-2518.
111. Klatzmann D, Valery CA, Bensimon G, et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma: Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther. 1998;9(17):2595-2604. (Pubitemid 29004632)
112. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther. 2000;11(17):2389-2401.
113. Eck SL, Alavi JB, Judy K, et al. Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trial. Hum Gene Ther. 2001;12(1):97-113. (Pubitemid 32044471)
114. Colombo F, Barzon L, Franchin E, et al. Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther. 2005;12(10):835-848. (Pubitemid 43086285)
115. Ren H, Boulikas T, Lundstrom K, et al. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene - a phase I/II clinical protocol. J Neurooncol. 2008;64(1-2):147-154. (Pubitemid 36992469)
116. Okada H, Pollack IF, Lieberman F, et al. Gene therapy of malignant gliomas: a pilot study of vaccination with autologous irradiated glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response. Hum Gene Ther. 2001;12(5):575-595. (Pubitemid 32511078)
117. Lassman AB, Rossi MR, Raizer JJ, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res. 2005;11(21):7841-7850.
118. Prados MD, Lamborn KR, Chang S, et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol. 2006;8(1):67-78. (Pubitemid 43154453)
119. Preusser M, Gelpi E, Rottenfusser A, et al. Epithelial growth factor receptor inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study. J Neurooncol. 2008;89(2):1211-1218
120. Franceshi E, Cavallo G, Lonardi S, et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer. 2007;96(7):1047-1051. (Pubitemid 46608313)
121. de Groot JF, Gilbert MR, Aldape K, et al. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol. 2008;90(1):89-97.
122. Brown PD, Krishnan S, Sarkaria JN, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group study N1077. J Clin Oncol. 2008;26(34):5603-5609.
123. Krishnan S, Brown PD, Ballman KV, et al. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys. 2006;65(4):1192-1199. (Pubitemid 43914202)
124. Schwer AL, Damek DM, Kavanagh BD, et al. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2008;70(4):993-1001.
125. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004;22(1):133-142. (Pubitemid 41095125)
126. Reardon DA, Quinn JA, Vredenburgh JJ, et al. Phase I trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res. 2006;12(3):860-868.
127. Prados MD, Yung WKA, Wen PY, et al. Phase-I trial of gefitinib and temozolomide in patients with malignant glioma: a North American Brain Tumor Consortium study. Cancer Chemother Pharmacol. 2008;61(6):1059-1067.
128. Preusser M, Gelpi E, Rottenfusser A, et al. Epithelial growth factor receptor inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study. J Neurooncol. 2008;89(2):211-218.